ES536547A0 - Un conjugado de una molecula biologicamente activa - Google Patents

Un conjugado de una molecula biologicamente activa

Info

Publication number
ES536547A0
ES536547A0 ES536547A ES536547A ES536547A0 ES 536547 A0 ES536547 A0 ES 536547A0 ES 536547 A ES536547 A ES 536547A ES 536547 A ES536547 A ES 536547A ES 536547 A0 ES536547 A0 ES 536547A0
Authority
ES
Spain
Prior art keywords
biologically active
molecula
conjugate
metallothionein
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES536547A
Other languages
English (en)
Other versions
ES8605105A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Publication of ES536547A0 publication Critical patent/ES536547A0/es
Publication of ES8605105A1 publication Critical patent/ES8605105A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES536547A 1983-10-06 1984-10-05 Un conjugado de una molecula biologicamente activa Expired ES8605105A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/539,733 US4732864A (en) 1983-10-06 1983-10-06 Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules

Publications (2)

Publication Number Publication Date
ES536547A0 true ES536547A0 (es) 1986-02-16
ES8605105A1 ES8605105A1 (es) 1986-02-16

Family

ID=24152436

Family Applications (1)

Application Number Title Priority Date Filing Date
ES536547A Expired ES8605105A1 (es) 1983-10-06 1984-10-05 Un conjugado de una molecula biologicamente activa

Country Status (17)

Country Link
US (1) US4732864A (es)
EP (1) EP0137457B1 (es)
JP (2) JPS60166625A (es)
KR (1) KR860001151B1 (es)
AT (1) ATE32730T1 (es)
AU (1) AU578428B2 (es)
CA (1) CA1248090A (es)
DE (1) DE3469536D1 (es)
DK (1) DK162105C (es)
ES (1) ES8605105A1 (es)
FI (1) FI81263C (es)
GR (1) GR80560B (es)
IE (1) IE55709B1 (es)
IL (1) IL73183A (es)
NO (1) NO166267C (es)
NZ (1) NZ209788A (es)
ZA (1) ZA847797B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707352A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
NO167124C (no) * 1985-04-03 1991-10-09 Du Pont Merck Pharma Fremgangsmaate for fremstilling av et spormerket konjugat av metallthionein og biologisk aktivt molekyl.
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JP2515357B2 (ja) * 1986-01-16 1996-07-10 ザ・ジェネラル・ホスピタル・コ−ポレ−ション 炎症の診断方法および治療方法
US6165729A (en) * 1986-04-30 2000-12-26 Hyperion Catalysis International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5591581A (en) 1986-04-30 1997-01-07 Igen, Inc. Electrochemiluminescent rhenium moieties and methods for their use
US6451225B1 (en) 1986-04-30 2002-09-17 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US4877599A (en) * 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
ATE259064T1 (de) * 1987-11-04 2004-02-15 Igen Int Inc Lumineszente rhenium-komplexe und verfahren zur herstellung
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
USH735H (en) 1988-03-30 1990-02-06 The United States Of America As Represented By The United States Department Of Energy Lead-203 as a label for radioimaging
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
US6702986B1 (en) 1988-04-29 2004-03-09 Igen International, Inc. Electrochemiluminescent reaction utilizing amine-derived reductant
US5726153A (en) * 1988-05-02 1998-03-10 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5218128A (en) * 1988-06-15 1993-06-08 Centocor, Inc. Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
WO1990006323A2 (en) * 1988-11-29 1990-06-14 Centocor, Inc. Chimeric proteins incorporating a metal binding protein
US5078985A (en) * 1989-08-09 1992-01-07 Rhomed, Incorporated Radiolabeling antibodies and other proteins with technetium or rhenium by regulated reduction
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
US5759515A (en) * 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
JP3070763B2 (ja) * 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5700444A (en) * 1992-02-20 1997-12-23 Rhomed Incorporated Chemotactic peptide pharmaceutical applications
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
EP0515516B1 (en) * 1990-02-15 2002-01-16 University of North Carolina Methods for identifying heterofunctional fusion proteins
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
ATE188387T1 (de) * 1991-02-08 2000-01-15 Diatide Inc Technetium-99m markierte polypeptide zur bildformung
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US7238340B1 (en) 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
US6391590B1 (en) * 1991-10-21 2002-05-21 The Regents Of The University Of California Recombinant streptavidin-metallothionein chimeric protein having biological recognition specificity
US5738838A (en) * 1992-02-20 1998-04-14 Rhomed Incorporated IKVAV peptide radiopharmaceutical applications
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
US5643549A (en) * 1992-02-20 1997-07-01 Rhomed Incorporated Leukostimulatory agent for in vivo leukocyte tagging
US5326856A (en) * 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5338686A (en) * 1992-04-29 1994-08-16 Hellerstein Marc K Method for measuring in vivo synthesis of biopolymers
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
US6203775B1 (en) * 1993-03-19 2001-03-20 The General Hospital Corporation Chelating polymers for labeling of proteins
JPH08510250A (ja) * 1993-05-17 1996-10-29 イムノメディクス，インコーポレイテッド ビオチンまたはアビジンと金属キレート化タンパク質との複合体による病変の検出および治療法の改善
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
AU7261994A (en) * 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
WO1995004753A1 (en) * 1993-08-11 1995-02-16 University Of New Mexico Compositions of fusion proteins containing metallothionein and targeting-protein structural components
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6331285B1 (en) 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US7632651B2 (en) 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
EP1100473A2 (en) 1998-07-28 2001-05-23 InnerDyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
KR20020002354A (ko) * 1998-10-13 2002-01-09 추후제출 안정화된 생활성 펩티드 및 이들을 동정, 합성 및이용하는 방법
US7666609B1 (en) * 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
WO2000038654A1 (en) * 1998-12-23 2000-07-06 Vallee Bert L Synthetic and therapeutic methods for the alpha and beta domains of metallothionein
AU771248B2 (en) * 1999-01-22 2004-03-18 Martek Biosciences Corporation Simple method for labeled conjugate production
ES2198171B1 (es) * 2000-09-06 2005-04-16 Provital, S.A. Composicion cosmetica y/o farmaceutica conteniendo metalotioneina.
US7385025B2 (en) 2000-12-19 2008-06-10 Palatin Technologies, Inc. Metallopeptide compounds
US20020117169A1 (en) 2001-02-27 2002-08-29 Kurz Daniel R. Cover and applicator for a portion of a mammalian body
US20030003051A1 (en) * 2001-06-11 2003-01-02 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
AU2003241024A1 (en) * 2002-05-29 2003-12-19 Immunomedics, Inc. Methods and compositions for radioimmunotherapy of brain and cns tumors
WO2004034059A1 (en) * 2002-10-11 2004-04-22 Sentina Biotechnology Incorporated Methods for detection of breast cancer
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
KR20110119813A (ko) 2003-09-17 2011-11-02 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 메카니즘-기초 표적화된 췌장 베타 세포 영상화 및 치료법
EP1711618B1 (en) 2003-12-23 2010-08-04 Mount Sinai Hospital Corporation Methods for detecting markers associated with endometrial disease or phase
CN1946741B (zh) * 2004-03-31 2012-09-05 佳能株式会社 金结合蛋白及其用途
WO2006118615A2 (en) * 2004-12-16 2006-11-09 Brandeis University Clonable tag for purification and electron microscopy labeling
EP1865972B1 (en) * 2005-03-23 2013-11-06 CHS Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
US8357720B2 (en) * 2005-03-23 2013-01-22 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
US8765808B2 (en) * 2005-03-23 2014-07-01 Chs Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
US20090312238A1 (en) * 2006-05-03 2009-12-17 Florida Atlantic University Protection Against Oxidative Damage in Cells
GB0621894D0 (en) * 2006-11-02 2006-12-13 Iti Scotland Ltd Magnetic recognition system
US20080269065A1 (en) * 2007-04-30 2008-10-30 Syntrix Biosystems, Inc. Conformationally Constrained Analytical Probes
US20100256464A1 (en) * 2007-05-14 2010-10-07 Dr. Susan Love Research Foundation Device for determining risk of developing breast cancer and method thereof
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
GB0808086D0 (en) * 2008-05-02 2008-06-11 Iti Scotland Ltd Magnetic proteins for in vivo imaging
CA2727803C (en) * 2008-05-13 2013-03-12 University Of Kansas Metal abstraction peptide (map) tag and associated methods
US9603954B2 (en) 2009-07-22 2017-03-28 Actinium Pharmaceuticals Inc. Methods for generating radioimmunoconjugates
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
WO2012021969A1 (en) 2010-08-16 2012-02-23 Mount Sinai Hospital Markers of the male urogenital tract
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
EP3409297A1 (en) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
WO2019057598A1 (en) 2017-09-20 2019-03-28 Alfarim Medical Holding B.V. OPTIMAL 225ACTINIUM - 213BISMUTH GENERATOR FOR ALPHA PARTICLE RADIO IMMUNOTHERAPY
AU2022262350B2 (en) 2021-04-20 2026-05-07 Terrapower Isotopes, Llc Titania based generators for ac-225 generation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56125317A (en) * 1980-03-08 1981-10-01 Nippon Mejifuijitsukusu Kk Stable radioactive diagnosticum with radioactive metallic mark
NO169947C (no) * 1981-10-27 1992-08-26 Hybritech Inc Fremgangsmaate for fremstilling av et monoklonalt antistoff til et tumorassosiert antigen
CA1222691A (en) * 1981-12-29 1987-06-09 Wilhelmus T. Goedemans Method of preparing radionuclide-labelled proteins, in particular antibodies or antibody fragments
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies

Also Published As

Publication number Publication date
KR860001151B1 (ko) 1986-08-18
ATE32730T1 (de) 1988-03-15
IE842539L (en) 1985-04-06
US4732864A (en) 1988-03-22
KR850002961A (ko) 1985-05-28
NO166267B (no) 1991-03-18
EP0137457A3 (en) 1985-08-14
GR80560B (en) 1985-02-06
DK162105C (da) 1992-02-17
FI843930A0 (fi) 1984-10-05
ZA847797B (en) 1986-05-28
FI843930L (fi) 1985-04-07
NO844017L (no) 1985-04-09
FI81263C (fi) 1990-10-10
DK162105B (da) 1991-09-16
AU3362984A (en) 1985-04-18
EP0137457A2 (en) 1985-04-17
EP0137457B1 (en) 1988-03-02
DK480284D0 (da) 1984-10-05
ES8605105A1 (es) 1986-02-16
CA1248090A (en) 1989-01-03
JPH0470320B2 (es) 1992-11-10
NZ209788A (en) 1988-10-28
DK480284A (da) 1985-04-07
IL73183A0 (en) 1985-01-31
DE3469536D1 (en) 1988-04-07
AU578428B2 (en) 1988-10-27
IL73183A (en) 1991-09-16
FI81263B (fi) 1990-06-29
IE55709B1 (en) 1990-12-19
JPS60166625A (ja) 1985-08-29
JPH01294700A (ja) 1989-11-28
NO166267C (no) 1991-06-26

Similar Documents

Publication Publication Date Title
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
CY1113355T1 (el) Χρηση θεραπειας νευροτοξινης για θεραπευτικη αγωγη ουρολογικων και σχετικων διαταραχων
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
ATE164522T1 (de) Carboxamid-modifizierte polyamin-chelatoren, radioaktive komplexe und konjugate
BR9107074A (pt) Imunorreagente radioativo de marcacao,composicao e processo de formacao de imagem diagnostica,composicao terapeutica,processo de tratamentod e silios doentios e composicao da materia
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
NO960586L (no) Öket tverrbinding av naturlig vev
NO894326D0 (no) Fremgangsmaate for fremstilling av et bufunksjonelt chelateringsmiddel.
IT1264965B1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ES8403884A1 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
FR2550944B1 (fr) Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
FI954645A0 (fi) (S)-alfa-fenyyli-2-pyridiinietanamiini-(S)-malaatti ja sen käyttö lääkkeenä
GR3005231T3 (es)
FR2370053A1 (fr) Acides 7-acylamino-3-(1-(2,3-dihydroxypropyl)tetrazole-5-ylthiomethyl)-3-cepheme-4-carboxyliques et leur application en therapeutique
RU94005399A (ru) Устройство для иглорефлексотерапии
UA18225A (uk) Спосіб лікуваhhя раh
RU94001222A (ru) Способ лечения воспаленных тканей организма
UA26077C2 (uk) Аплікаційhий матеріал лікувальhо-профілактичhого призhачеhhя
ES1032013U (es) Dispositivo electropolarizado.
GEP19991402B (en) Method of treatment of tube sterility of an inflammatory genesis
ES1003621U (es) Visera perfeccionada.
IT1274015B (it) Uso del ceruletide (takus) nel trattamento della psoriasi
DE69003532D1 (de) Therapeutische zusammensetzung und kit für die behandlung der rheumatischen polyarthritis.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19971001